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ABSTRACT
Introduction: Bipolar disorder is a chronic
disease characterized by periods of mania or
hypomania, depression, or a combination of
both (mixed state). Because bipolar disorder is
one of the leading causes of disability, it
represents an important economic burden on
society. Asenapine (ASE) is a new second-
generation antipsychotic developed and
approved for the treatment of manic or mixed
episodes associated with bipolar disorder. The
objective of the present study was to assess the
cost-effectiveness of ASE compared to
olanzapine (OLA) in the treatment of patients
experiencing mixed episodes associated with
bipolar I disorder in the context of the Italian
National Health Service (NHS).
Methods: A pharmacoeconomic model was
developed to simulate the management of
Italian bipolar I patients with mixed episodes
over a 5-year time horizon by combining
clinical parameters with resource utilization.
An expert panel of Italian psychiatrists and
health economists was responsible for adapting
a UK model to the Italian context. The primary
outcome measure of the economic evaluation
was the incremental cost effectiveness ratio,
where effectiveness is measured in terms of
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quality adjusted life-years gained. Scenario
analyses, sensitivity analyses, and a
probabilistic sensitivity analysis were
performed to test the robustness of the model.
Results: This pharmacoeconomic model
showed that ASE resulted to be dominant over
OLA; in fact, ASE was associated with lower
direct costs (derived largely by the savings from
hospitalizations avoided) and also generated a
better quality of life. Results were robust to
changes in key parameters; both scenario
analyses and sensitivity analyses demonstrated
model reliability.
Conclusions: Results from this study suggest
that the management of bipolar I patients with
mixed episodes using ASE as alternative to OLA
can lead to cost saving for the Italian NHS and
improve patients quality of life.
Keywords: Asenapine; Bipolar disorder; Cost-
effectiveness analysis (CEA); Mixed episodes;
Olanzapine; Psychiatry
INTRODUCTION
Bipolar disorder is a chronic disease
characterized by periods of mania or
hypomania (episodes of elevated moods,
extreme irritability, decreased sleep, and
increased energy), depression (overwhelming
feelings of sadness, anhedonia, suicidal
thoughts) or a combination of both (named as
mixed state). The exact cause of the condition is
unknown, but genetic, physiological,
neurological, psychosocial, and environmental
factors may be involved. According to the
Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition, the diagnosis of
bipolar type I requires the presence or the
history of at least one manic or mixed episode,
whereas bipolar disorder type II differs from
type I only by the presence of hypomania but
no manic episodes [1].
The prevalence of bipolar I disorder in Italy is
estimated to be approximately 1–2%, even if the
true prevalence is likely to be much higher
because it is frequently under-diagnosed, largely
due to the fact that it is difficult to diagnose
correctly [2]. Because bipolar disorder is one of
the leading causes of disability, especially in
active populations, it represents an important
economic burden on society [3]. A study
evaluating the cost of bipolar disorder in the
UK has estimated a cost of £198.7 million per
year, with hospitalization accounting for the
largest component of direct costs [4].
Mixed episodes are a common feature of
bipolar I disorder and they are associated with
more severe symptoms and outcomes [5, 6];
moreover, this type of episode tends to last
longer than manic and depressive episodes [7]
and is more commonly associated with
substance abuse, anxiety disorders, and
suicidality [8–10]. Treatment of bipolar mixed
states is often challenging as response is usually
poorer than in manic or depressive episodes [11]
and involves the use of lithium (Li), sodium
valproate (VPA), and second-generation
antipsychotics (SGAs) [12]. Currently, the best
evidence for efficacy as monotherapy for the
acute treatment of mixed state is provided for
anticonvulsants followed by the atypical
antipsychotics: aripripazole, asenapine (ASE),
paliperidone, and ziprasidone [13]. There was
also very strong evidence for the use of
olanzapine (OLA) as monotherapy or as add-
on to Li or VPA [13].
In 2013, the first meta-analysis of the efficacy
of SGAs in mixed episodes was published,
suggesting that some of these drugs are
effective in reducing not only manic but also
depressive symptoms in patients with mixed
episodes [14]. SGAs, particularly ASE, OLA,
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aripriprazole, paliperidone, risperidone, and
ziprasidone were reported to be efficacious on
maniac symptoms of mixed episodes, while ASE
and OLA also appear to be moderately
efficacious in treating depressive symptoms of
mixed episodes [14, 15].
ASE is a new SGA developed and approved in
the USA for the acute treatment, as
monotherapy or adjunctive therapy with
either Li or VPA, of manic or mixed episodes
associated with bipolar I disorder. Whether used
as monotherapy or as adjunctive therapy with
Li or VPA, the use of ASE in responding patients
is generally recommended by the Food and
Drug Administration to be continued beyond
the acute response [16]. In Europe, in September
2010, the European Medicines Agency has
authorized the marketing of this molecule for
the treatment of moderate to severe manic
episodes associated with bipolar I disorder in
adults.
Focusing on mixed episode patients, Azorin
et al. [17] assessed the efficacy of ASE using post
hoc analyses on pooled data from two identical
3-week, randomized, double-blind, placebo-
and OLA-controlled trials [18, 19] and their
9-week double-blind, OLA-controlled extension
study [20]. At week three, ASE was found to be
significantly superior to both placebo and OLA
both on manic and depressive symptoms
improving Montgomery–A˚sberg Depression
Rating Scale (MADRS) and Young Mania
Rating Scale (YMRS) scores. At week 12,
further decrease in YMRS and in MADRS total
scores was observed with ASE, although not
reaching a statistically significant difference.
Although no statistically significant difference
was observed between ASE and OLA in
composite response rate or mean reduction on
either score, these findings suggest a potential
difference in the way the two drugs work in
mixed episodes.
Even though cost-effectiveness of different
SGAs in the treatment of patients experiencing
a manic episode associated with bipolar I
disorder has been studied in numerous
analyses and in different contexts [21–26],
only a few studies [27, 28] have explored the
role of these drugs in patients with mixed
episodes.
The current study evaluates from an Italian
National Health Service (NHS) perspective, the
cost-effectiveness of ASE compared to OLA in
the treatment of patients experiencing mixed
episodes associated with bipolar I disorder.
Comparison against SGAs was only possible
with OLA due to lack of randomized studies
comparing efficacy of ASE versus other
antipsychotics in the treatment of the
subpopulation with mixed episodes.
Furthermore, OLA was the best comparator
based on proven efficacy and market-share [13].
METHODS
The analysis in this article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
Model Introduction
The pharmacoeconomic model was developed
to simulate the management of Italian bipolar I
patients with mixed episodes over a five-year
time horizon by combining clinical parameters
with resource utilization.
An expert panel, composed of five
psychiatrists from different Italian regions and
two health economists from an independent
agency, was responsible for adapting a model
developed by Sawyer et al. [27] from the UK into
an Italian perspective.
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Efficacy was informed by a post hoc analysis of
two short-term clinical trials, with response
measured as a composite MADRS and YMRS [17].
Probabilities of discontinuation and relapse to
manic, mixed, and depressive episodes were
sourced from published meta-analyses [29, 30].
The primary outcome measure of the
economic evaluation is the incremental cost-
effectiveness ratio (ICER), where effectiveness is
measured in terms of quality-adjusted life years
(QALYs) gained.
Because costs were considered from the
Italian NHS perspective, only direct medical
costs, expressed in Euro, could be evaluated.
The pharmacoeconomic model was developed
using Microsoft Office Excel 2007 (Microsoft
Corporation, Albuquerque, NM, USA) software.
Description of Model
The model comprises an acute phase and a
maintenance phase. The acute phase (Fig. 1) is
designed using a standard decision tree model,
and it covers the three three-week initial
treatment periods. The maintenance phase is
designed using a Markov model, and it follows
patients for four-week cycles for a five-year follow-
up period as their condition stabilizes and the goal
of treatment shift into relapse prevention. A
survey on treatment guidelines [31]
demonstrates a lack of consensus regarding the
appropriate time tochange treatment strategies in
case of partial or non-response during an acute
manic episode, with recommendations ranging
from 2 to 12 weeks. In the absence of firm
evidence and given the high risk of suicide in
mixed episodes, a shorter duration (3 weeks)
during which to assess response to treatment
was considered appropriate.
Hypothetical patients enter the acute phase
of the model experiencing a mixed episode
being allocated to either ASE or OLA treatment
arms. Non-responder patients will have an
adjunctive therapy with VPA (ASE/OLA ? VPA;
2nd line), and, if they are still not responding
for the 2nd line, a switch to adjunctive Li (ASE/
OLA ? Li; 3rd line). The sequence of adjunctive
therapy with VPA as 2nd line and Li as third line
was based on the fact that most guidelines
mention the superiority of VPA over Li to treat
mixed episodes [13]. These assumptions were
informed by clinical expert opinion.
After the 9-week model acute phase, patients
non-respondent to any of the treatment lines
enter the Markov model as ‘‘Non-responder’’ on
triple therapy (ASE/OLA ? VPA ? Li). If the
response criteria are met for any treatment
lines, patients enter directly in the
Fig. 1 Acute phase model structure
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maintenance Markov model in the ‘‘Subacute
on Tx’’ health state.
The maintenance phase of the economic
model (Fig. 2) is designed to follow hypothetical
patients for 5 years after the index mixed
episode, irrespective of whether they did or
did not respond to treatment during the acute
phase. Five years was deemed a sufficient length
of time by clinical experts to capture the longer-
term aspects of bipolar disorder treatment, such
as stabilization after an acute episode, possible
discontinuation of therapy, management and
prevention of relapse episodes, and mortality.
As stated above, patients who have responded
to either monotherapy or adjunctive treatments
(1st-, 2nd-, or 3rd-line responders) in the acute
phase enter the maintenance phase of the
economic model in a subacute health state (i.e.,
a transitory state in which all responding patients
must pass before reach stability), whereas
patients who have not responded to any
therapy in the acute phase will enter the
maintenance phase as non-responders.
Patients will stay in these health states until
they respond to treatment (if non-responders,
transition from ‘‘Non-responder’’ state to
‘‘Subacute on Tx’’ state) and achieve euthymia
(transition from ‘‘Subacute on Tx’’ to ‘‘Stable on
atypical antipsychotic [AA] Tx’’). Once patients
achieve euthymia while on treatment, they may
discontinue treatment with SGA remaining
with VPA alone or Li alone (defined minimal
treatment and represented in the model as
‘‘Stable minimal Tx’’ state). Stable patients
(either on regular antipsychotic treatment or
on the minimal treatment described above) can
relapse and experience a manic, mixed, or
depressive episode. Following relapse, patients
across both arms switch to treatment with
quetiapine (QTP) ? VPA or QTP ? Li (a 50/50
split is assumed), remaining on this treatment
until the end of the modeled time horizon. This
simplified approach ensures that all patients
follow the same long-term prognosis and costs.
At any point in the model, patients can die.
Model Parameters
Response, Relapse, Discontinuation, and other
Probabilities
Response to the acute phase with first line
monotherapy (ASE or OLA) is defined in this
model as C50% improvement from baseline in
the YMRS and MADRS scores within 3 weeks,
and sourced from the post hoc analysis of the
ARES trial on mixed patients [17].
Comparative response rates for ASE and OLA
in combination with VPA or Li on the
composite YMRS and MADRS outcome are not
available from clinical trial data; therefore, for
the adjunctive therapies (2nd and 3rd line
treatments), differently from the UK model in
which 95% confidence intervals upper limits
were used, the authors applied the ASE ? VPA/
Li response data from Apollo 12
(Clinicaltrials.gov #NCT00145470) trial
Fig. 2 Maintenance phase model structure. TX treatment, AA atypical antipsychotic
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assuming the same response for both ASE and
OLA (Table 1) [32]. This assumption was
deemed reasonable by clinical expert opinion.
The annual risks of relapse used in the
maintenance phase model for each treatment
arm are reported in Table 1. Most of these values
were sourced from a systematic review and
network meta-analysis by Soares-Weiser et al.
[30]. As ASE was not available in this review, it
was assumed that the annual risk of relapse for
ASE was the same as for OLA. Similarly, as no
data were available on the efficacy of
combination therapies in relapse prevention, it
was assumed that risk of relapse was related to
the last added treatment.
Since probabilities of relapse from Soares-
Weiser et al. [30] were stratified by manic/mixed
or depressive episode, the model needed a
further breakdown between patients
experiencing a recurrent manic episode versus
a recurrent mixed episode. For this reason, the
authors applied the probability of a relapse split
between mania and mixed episodes from the
study by Vieta and colleagues (53.3% mania and
46.7% mixed) [33].
Treatment discontinuation in the model is
defined as patients discontinuing their
antipsychotic treatment and moving on to a
‘‘minimal treatment’’, which was assumed to be
VPA alone for 50% of patients and Li alone for
the other 50%. As in the UK model, probability
of discontinuing treatment with the initial drug
during periods of disease stability was calculated
by applying a risk ratio from a published meta-
analysis of clinical trials [34] to an underlying
baseline probability of discontinuing on
placebo. The placebo discontinuation rates are
based on a published discrete-event simulation
model for patients with acute bipolar
depression [29]. Again, as ASE-treatment
discontinuation risk was not available in the
meta-analysis, it was assumed that the
treatment discontinuation probability for ASE
was the same as for OLA (Table 1).
Patients who failed to respond to the 1st-,
2nd-, and 3rd-line treatments in the acute phase
enter the maintenance phase as non-responders
and on triple therapy (AA ? VPA ? Li). Due to
lack of data, the authors have assumed a 35%
per cycle probability of reaching the subacute
health state and varied the base case probability
in a sensitivity analysis from 0% to 100%.
The subacute health state was implemented
in the model as a temporary tunnel state,
through which responding patients must
transition before achieving stable euthymia.
From this temporary tunnel state, a monthly
probability of achieving euthymia was
estimated to be 60% based on expert opinion.
Also this probability has been tested by the
authors with a sensitivity analysis from 0% to
100%.
The mortality risk, stratified by causes
(suicide and non-suicide), was calculated
starting from the interim life tables for Italy
[35] and applying the general population
annual risk of suicide from the same source.
Finally, the authors applied standardized
mortality ratios for suicide (11.53) and non-
suicide (1.69) retrieved from Angst et al. [36] to
define the mortality risk among patients with
bipolar I disorder.
Adverse Event
The model incorporates two common adverse
events due to antipsychotic medication: weight
gain and extrapyramidal symptoms (EPS),
whose incidences, that are different according
to drug regimen, were retrieved from several
trials [17, 33, 37, 38]. Weight gain is associated
with all bipolar disorder drugs; so, this adverse
event was associated with all drugs. For
combination therapies, the incidence of
weight gain is set to equal that of the drug
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Table 1 Response rates, annual risks of relapse, treatment discontinuation probabilities, and incidence values for weight
gain and EPS
Treatment drug Response (95% CI) Source
Response rates
ASE 0.463 (0.340; 0.589) [17]
OLA 0.375 (0.274; 0.485) [17]
ASE ? VPA/Li 0.342 (0.268; 0.416) [32]
OLA ? VPA/Li 0.342 (0.268; 0.416) Assumed the same as ASE ? VPA/Li
Treatment drug Manic/Mixed Depression Source
Annual risks of relapse
ASE 0.08 0.14 Assumed the same as OLA
OLA 0.08 0.14 [30]
VPA 0.23 0.05 [30]
Li 0.20 0.07 [30]
Li ? VPA 0.23 0.05 Assumed to be the max value between VPA and Li
QTP ? Li/VPA 0.14 0.22 [33]
Minimal TX 0.215 0.06 Average of Li and VPA
Treatment drug Probability Source
Treatment discontinuation probabilities
Placebo 0.017 [34]




Li ? VPA 0.014 Assumed to be the max value between VPA and Li
QTP ? Li/VPA 0.012 [29]
Treatment drug Weight gain EPS Source
Incidence values for weight gain and EPS
ASE 0.138 0.112 [17]
OLA 0.0764 0.098 [17]
VPA 0.079 0.032 [37]
Li 0.029 0.028 [38]
QTP ? VPA ? Li 0.144 0.0092 [33]
ASE asenapine, EPS extrapyramidal symptoms, Li lithium, OLA olanzapine, QTP quetiapine, VPA sodium valproate
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with the highest incidence. EPS is typically
associated with atypical antipsychotics and not
with mood stabilizers; so, EPS are assumed to
occur only during the atypical antipsychotics
treatment. Both adverse events are assumed to
occur independently. The incidence values for
weight gain and EPS are reported in Table 1.
Utilities
Utility values for the model health states and
adverse events were derived from the UK
model [24], except for inpatient and
outpatient mixed episodes utilities; since no
data were available in literature, the authors
agreed to set the same values as those set for
mania (Table 2).
The utility values of the general population
applied in the model were converted to
multipliers using the formulae of Ara and
Brazier [39], which take into account the age-
and gender-distribution relative to the study
population.
In order to derive the condition-specific
utility values for the model health states and
adverse events, a multiplicative approach was
used considering multipliers defined according
to different health states and adverse events.
Costs and Resource Utilization
This model considered only direct medical costs
including those associated with drug
acquisition, general practitioner (GP) visits and
specialist visits, examinations, and
hospitalizations. This model is set in the
Italian NHS perspective. Therefore, only the
costs directly reimbursed by the NHS were
considered. Since a 5-year time horizon was
set, a discounting of 0.035% was applied.
Drug costs were calculated based on prices
listed on the Italian Drug Agency website [40].
For generic drugs, the authors considered prices
reimbursed by the NHS, whereas for ASE, the
only branded drug, the authors considered the
public price applying a discount for NHS (12.5%
for drugs between €103.29 and €154.94) after
VAT. Treatment doses used in the analysis were
the weighted average of the daily doses found in
literature. The unit costs per mg, daily doses
(mg), and daily costs for the drugs used in this
model are reported in Table 3.
In order to test the dosages applied in the
model, the authors developed a scenario
analysis adopting the recommended daily
doses from the summary of product
characteristics (SPCs) for both the acute phase
and the maintenance phase (Table 3).
Resource utilization was differentiated
according to drug regimen and for the acute
and maintenance phases, and it was assessed to
reflect the Italian standard clinical practice.
Full blood count, liver panel, blood urea,
creatinine, thyroid function (i.e., thyroid-
stimulating hormone), serum Li
Table 2 Utility values
Condition Utility value Source
Subacute 0.8 [39]
Stable 0.84 [17]
Mania IP 0.245 [39]
Mania OP 0.585 [39]
Mixed IP 0.245 Assumed the same as
Mania IP
Mixed OP 0.585 Assumed the same as
Mania OP
Depression IP 0.29 [39]
Depression OP 0.605 [46]
Weight gain 0.825 [47]
EPS 0.722 [47]
EPS extrapyramidal symptoms, IP inpatient, OP
outpatient
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concentration, electrocardiogram, electrolytes,
glucose test, lipid profile, prolactin, serum
valproic acid concentration, amylase, and
ammonium were considered and their costs
were taken from the 2014 pricelist from Italian
Ministry of Health website (Tariffa Unica
Convenzionale [TUC]) [41].
Health state associated costs were estimated
to differ on a yearly base and depending upon
the episode type (i.e., acute manic, mixed, and
depressive episode) and health state. The
assumptions of health state costs follow the
ones described by Soares-Weiser et al. [30] and
adopted also in the UK model [27]. Since the
Soares-Weiser approach classified services based
on the type of management (inpatient,
outpatient, and crisis resolution team), the
authors readapted this approach to the Italian
context (Table 4) introducing Day Hospital
service. Furthermore, an adjunctive scenario
analysis using a different management
breakdown discussed by the expert panel was
performed (Table 4). Since Soares-Weiser et al.
[30] reported information on mania and
depression only, the authors assumed the
same management breakdown and healthcare
services utilization for mixed episode and
mania.
Healthcare services costs and utilizations are
presented in Table 4 and unit costs were
retrieved from the TUC 2014. The authors
assumed that the cost for the stable health
state is the baseline cost and any relapse event
represents an additional cost.
As mentioned before, the main adverse
events for patients on treatment for bipolar I
disorder are weight gain and EPS. The weight
gain costs for the acute phase were a dietician
Table 3 Treatment costs considering daily doses from literature and summary of product characteristics (SPCs)
Treatment Unit cost per mg (€) Daily dose (mg) Daily cost (€)
Treatment costs considering daily doses from literature
Asenapine 0.22 18.3 4.07
Olanzapine 0.16 14.8 2.39
Quietiapine 0.003 613.8 2.05
Valproate 0.00004 1,735.4 0.68
Lithium 0.00002 1,126.3 0.19
Lithium ? Valproate – – 0.87
Treatment Daily dose (mg) Daily cost (€)
Acute Maintenance Acute Maintenance
Treatment costs considering daily doses from SPCs
Asenapine 20 10 4.45 2.22
Olanzapine 15 10 2.41 1.61
Quietiapine – 600 – 2.00
Valproate 1,500 1,500 0.59 0.59
Lithium 1,200 1,200 0.20 0.20
Lithium ? Valproate – – 0.79 0.79








































































































































































































































































































































































882 Adv Ther (2014) 31:873–890
visit cost and an additional GP visit cost; no cost
was associated to weight gain in the
maintenance phase. For EPS only medication
costs (biperidene 6 mg daily for 3 months) were




Cost-effectiveness analysis (CEA) is a method
for assessing the health gains in relation with
the costs of the different health interventions.
The main outcomes of the model are mean
costs and QALYs for treatment strategies and
the ICERs, which are the observed differences in
costs divided by differences in outcomes
between two alternative programs. The ICER
should be interpreted as the additional cost
required to gain an additional unit of health
outcome (i.e., QALY) when providing one
treatment rather than another one.
The associated probabilities, as long as
treatment costs, are subject to uncertainty, so
it may be necessary to test robustness of the
results obtained changing the model inputs or
using alternative parameters. In order to test the
robustness of the model results, sensitivity
analyses, scenario analyses, and probabilistic
analysis were performed.
Based on input from the expert panel, the
following analyses were developed:
• Scenario analysis on different drugs doses;
• Scenario analysis on different episode
management breakdown;
• Sensitivity analysis on transition probability
from non-responder to subacute state;
• Sensitivity analysis on transition probability
from subacute state to stable state.
Furthermore, a probabilistic sensitivity
analysis (PSA), in which all model parameters




Table 5 presents the results of the base case cost-
effectiveness analysis. ASE generated an increase
in QALYs of 0.0240 at average lower total costs
(i.e., €461.3 less) versus OLA, dominating its
comparator. Although the incremental
treatment costs (€1,134.5) are greater for ASE
than for OLA, savings in health state costs
generated by avoiding hospitalization
(€1,588.8) offset the total difference (Table 5).
An incremental gain of 0.0106 QALYs is
observed when the impact of adverse events is
excluded from quality of life calculations. Also
on this outcome, ASE dominates OLA in our
cost-effectiveness model (Table 5).
When only the acute phase is considered
(Table 5), referring to the first 9 weeks of
treatment after the mixed episode, ASE
generates greater benefits than OLA (0.0045
more QALYs and 0.0041 more QALYs when the
impact of adverse events is excluded) at lower
costs (€1,065.4 less). This result indicates that
the incremental QALYs and savings are derived
largely from the earlier response to treatment
during the acute phase.
Scenario Analyses
Table 6 describes the results of the scenario
analysis on different drug doses in which the
average doses derived from clinical studies used
in the base case were changed to the daily doses
from the SPCs (see Table 3).
Compared to OLA, also here ASE dominates
OLA, with a lower incremental total cost
Adv Ther (2014) 31:873–890 883
(€1,173.7 less than OLA), with respect to the
base case analysis (€461.3 less than OLA) thanks
to savings in the treatment costs (€422.2 vs.
€1,134.5, respectively).
The results of the scenario analysis on the
episodes management breakdown as derived
from the experts’ opinions rather than the one
used in the base case analysis (see Table 4) are
described in Table 6. Costs generated by ASE
and OLA are slightly lower than the ones of the
base case analysis (€31,219.7 and €31,528.4,
respectively) due to savings in health state costs.
The consistency of results between the base case
and the two scenario analyses supports the
robustness of the model.
Sensitivity Analyses
A sensitivity analysis on the probability of
changing health state from non-responders to
subacute health state during the maintenance
phase was performed. In the base case analysis,
this probability was set at 35% per cycle, while
the sensitivity analyses used a probability of 0%
and 100%. Results appeared sensitive to
variations in this parameter, but ASE remained












ASE strategy 3.6826 3.6495 4,716.2 86.8 28,107.9 32,911.0
OLA strategy 3.6720 3.6256 3,581.7 93.9 29,696.7 33,372.3
Incremental 0.0106 0.0240 1,134.5 -7.1 -1,588.8 -461.3
Base case results considering only the acute phase (9 weeks)
ASE strategy 0.0859 0.0833 119.2 19.4 18,471.7 18,610.3
OLA strategy 0.0818 0.0788 85.1 31.6 19,559.1 19,675.7
Incremental 0.0041 0.0045 34.1 -12.2 -1,087.4 -1,065.4
AEs adverse events, ASE asenapine, OLA olanzapine, QALYs quality-adjusted life years, w/ with, w/o without











Scenario analysis on different drugs doses
ASE strategy 3.6826 3.6495 3,404.7 86.8 28,107.9 31,599.4
OLA strategy 3.6720 3.6256 2,982.5 93.9 29,696.7 32,773.1
Incremental 0.0106 0.0240 422.2 -7.1 -1,588.8 -1,173.7
Scenario analysis on different episode management breakdown
ASE strategy 3.6884 3.6553 4,710.7 86.8 26,422.2 31,219.7
OLA strategy 3.6788 3.6322 3,577.0 93.9 27,857.5 31,528.4
Incremental 0.0096 0.0231 1,133.7 -7.1 -1,435.3 -308.6
AEs adverse events, ASE asenapine, OLA olanzapine, QALYs quality-adjusted life years, w/ with, w/o without
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dominant over OLA throughout the entire
range tested by the sensitivity analysis (Table 7).
Another sensitivity analysis was performed
on the probability of reaching the stable health
state from the subacute health state. In this
analysis the probability was changed from the
60% in the base case analysis to a range from 0%
to 100%. Also in this case ASE remained
dominant over OLA, similarly to the results
obtained in the base case analysis (Table 7).
Probabilistic Sensitivity Analyses
In the PSA, the probabilities of response,
relapse, discontinuation, and death, the health
state utility values and the unit costs were
probabilistically sampled 1,000 times
generating 1,000 samples.
Figure 3 represents the cost-effectiveness
plane in which the 1,000 estimates of mean
costs and mean effectiveness resulted from the
samples are plotted. In the majority of samples,
treatment with ASE resulted to be associated
with lower costs and increased QALYs compared
to OLA (lower-right quadrant).
The higher-right quadrant represents
samples that should need money investment
in order to achieve additional QALYs by using
ASE. In this study, due to the lack of official
willingness to pay threshold in Italy, we decided
to use an ICER threshold of €30,000 per QALY,
slightly lower than the one recognized by the
National Institute for Health and Care
Excellence (NICE; £20,000–30,000) [42].
Being so, with a willingness-to-pay threshold
set to €30,000 per QALY, treatment of patients
Table 7 Sensitivity analyses
Strategy QALYs w/AEs Total costs (€)
0% probability of reaching the subacute health state from the non-responders state
ASE strategy 3.1622 62,597.7
OLA strategy 3.0619 68,172.8
Incremental 0.1003 -5,575.1
100% probability of reaching the subacute health state from the non-responders state
ASE strategy 3.6660 31,887.2
OLA strategy 3.6447 32,178.1
Incremental 0.0213 -290.9
0% probability of reaching the stable health state from the subacute health state
ASE strategy 3.6489 34,039.6
OLA strategy 3.6245 34,671.2
Incremental 0.0244 -631.6
100% probability of reaching the stable health state from the subacute health state
ASE strategy 3.6498 32,409.8
OLA strategy 3.6260 32,795.5
Incremental 0.0238 -385.7
AEs adverse events, ASE asenapine, OLA olanzapine, QALYs quality-adjusted life years, w/ with
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experiencing a mixed episode with ASE has a
probability of 72.4% to be cost-effective
compared to OLA. PSA results also
demonstrate that ASE is dominant in 63.1% of
simulations.
DISCUSSION
In our pharmacoeconomic model, developed to
simulate the management of bipolar I patients
with mixed episodes over a 5-year time period
from the Italian NHS perspective, ASE results
superior to OLA. In fact, ASE is associated with
lower direct costs (-€461.3), derived largely by
the savings from hospitalizations avoided
(-€1,588.8), and also generates a better quality
of life (? 0.0240 QALYs). In line with results
obtained in clinical trials [18, 20], this
pharmacoeconomic study shows that the
greater health benefits and cost savings were
driven by earlier response to ASE treatment
during the acute phase and were well
maintained during long-term follow-up.
Results were robust to changes in key
parameters; both scenario analyses modeling
different health status transition probabilities,
drug doses, and episode management
breakdown, and sensitivity analyses
demonstrated model reliability, being these
scenario cases results comparable to base case
analysis. In particular, 63.1% out of the 1,000
PSA simulations found that ASE dominated OLA
and 72.4% showed an ICER lower than €30,000.
Hospitalizations generate the most
important costs, which account for about
85–90% of total expenses and, as highlighted
by Brunelle et al. [43], this burden increases
because inpatients that experienced a bipolar I
mixed episode may have a prolonged
hospitalization.
Results of the original model developed by
Sawyer et al. [27] are slightly different, with ASE
not dominating OLA, but generating an ICER
value (£1,302) lower than the one usually
applied by NICE [42]. Different results are
mostly attributable to the different inpatient
Fig. 3 PSA Scatter plot on cost-effectiveness plane for treatment with ASE versus OLA. ASE asenapine, OLA olanzapine,
PSA probabilistic sensitivity analysis, QALYs quality-adjusted life years
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and outpatient management between the two
Countries, as already described in the method
section.
A recent cost-effectiveness analysis
performed by Lachaine et al. [28] in Canada,
which focused on metabolic changes and their
complications on quality of life and survival,
showed a dominance of ASE in comparison with
OLA in both NHS and societal perspectives,
with an increase of 84.84 QALYs and a cost
decrease of 3,847,300 Canadian dollars (for NHS
perspective, while for societal perspective is
3,878,343 Canadian dollars) per 1,000 patients.
The foremost strength of this study is the
analysis methodology itself, since CEA accounts
not only for effectiveness and costs, but
includes also information on relapses,
hospitalizations, and adverse events. The role
of pharmacoeconomic models is central when it
is necessary to establish priorities in the
allocation of resources in a specific therapeutic
area. Indeed, they supply decision makers
within healthcare systems with useful tools to
make more rational and effective decisions.
The main study limitation concerns the lack
of publications regarding ASE treatment of
bipolar I type with mixed episode patients,
and adequate comparative data for other SGAs
in acute phase. In previous meta-analysis [14,
44] only post hoc analyses on pooled data from
clinical trials by McIntyre [18–20] were found
comparing ASE and OLA in mixed episodes.
Therefore, the authors of this
pharmacoeconomic study, similarly to the
authors of the previous pharmacoeconomic
study performed in the UK [27], used the post
hoc analyses by Azorin et al. [17] to derive the
efficacy and safety of treatments. The model
was validated by expert opinions.
Whilst important basic values, such as
efficacy and safety of OLA and ASE, were
available from these post hoc analyses,
evidence for other important parameters, i.e.
efficacy of adjunctive therapies, longer-term
efficacy of SGAs in relapse prevention, was not
available. Therefore, to minimize possible bias,
treatment efficacy of combination treatments
was assumed to be equal between ASE and OLA,
and assumption was made that, during
maintenance, in mixed episodes patients
efficacy in relapse prevention was similar for
both treatments arms.
Model robustness was tested using both
deterministic and probabilistic sensitivity
analyses; results proved the model reliability.
Another possible limitation could be that
only EPS and weight gain has been considered
among possible SGAs adverse events.
Nevertheless, since ASE showed a better safety
profile compared to OLA with regard to
metabolic effects including dyslipidemia and
type 2 diabetes mellitus [45], the impact of
other adverse events could possibly generate a
better performance for ASE.
CONCLUSION
Results from this study suggest that the
management of bipolar I patients with mixed
episodes using ASE as alternative to OLA can
lead to cost savings for Italian NHS and improve
patients’ quality of life. Future researches
specifically developed for this subset of
patients are needed to fill the gap of
information that are required by the cost-
effectiveness model and to permit the
comparison of ASE with other SGAs.
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